• Premium
  • Small Logo
  • About
  • Partner Pages
  • Support & FAQs
  • Log in

The Mandarin

The Mandarin
The Mandarin
  • Small Logo
  • Premium
  • Careers
    • Search SES Jobs
    • Career Advice
  • News
  • Editors' Picks
  • Portfolios
  • Events
  • Resource library
  • Small Logo
  • Premium
  • Careers
    • Search SES Jobs
    • Career Advice
  • News
  • Editors' Picks
  • Portfolios
  • Events
  • Resource library

Partner Content

Home Portfolio Health Winning the 5000 year fight against cancer

Winning the 5000 year fight against cancer

By Tom Burton

Monday October 9, 2017

Around the world governments and researchers are embracing audacious goals to reduce deaths resulting from cancer, with an increased confidence humanity’s 5000 year fight against cancer may just be achievable.

In Australia the Cancer Council has argued for a focused plan that leverages the work of recent governments in screening, anti-smoking measures, skin cancer awareness, drug availability and research will prevent at least 130,000 cancer deaths above current projections and prevent many thousands more cancer cases. In fiscal terms the council says this would generate economic returns in excess of $3 billion.

A global battle

In the US, former president Obama established the Cancer Moonshot project. The Blue Ribbon panel of experts came up with 10 transformative research recommendations for achieving the moonshot’s ambitious goal of making a decade’s worth of progress in cancer prevention, diagnosis, and treatment in just five years.

One of the American recommendations includes a major focus on data analytics and the building of a national ecosystem for sharing and analysing cancer data. This echoes similar moves in Australia, where a major consultation is now considering the protocols around secondary use of data in the My Health Record system for research, policy planning, system use, quality improvement and evaluation activities.

The most optimistic prognosis has come from the UK, where a 2015 report Overcoming Cancer in the 21st Century by researchers from Kings College and University College of London concluded: “It is realistic to expect that by 2050 nearly all cancer related deaths in children and adults aged up to (say) 80 years will have become preventable through life style changes and because of the availability of protective technologies and better pharmaceutical and other therapies.”


The Mandarin presents: Beating Cancer — an expert forum on how Australia can best fight our greatest killer

We have seen remarkable public benefits from the sustained efforts to reduce heart disease. How can we apply the same lessons of sustained investment and innovation to cancer? Join an internationally acclaimed expert panel at a special luncheon seminar October 24 at the National Portrait Gallery, as we explore how governments best prioritise resources, investment and targeted innovative treatments, and the societal return from winning the fight against cancer.


According to UCL Emeritus Professor of Pharmaceutical and Public health policy David Taylor, “What makes this a special point in history is that cancers are in the process of becoming either preventable or effectively curable.”

The report, which was funded by the Boots UK pharmacy group, argued that while cancer is responsible for around a quarter of all deaths, the cost of cancer treatment was about 7% of all healthcare spending in the UK. The report noted drug treatments typically represent about a fifth of the total cost of cancer care, which translates to about 0.1% to 0.2% of GDP. Australian figures are broadly consistent with these UK numbers.

The Australian experience

On current trends 131 Australians a day die from cancer, with an average of 367 people a day diagnosed with a new case of cancer. Cancer is also Australia’s leading cause of loss of healthy life years.

But while death rates as a proportion of population have fallen by about a quarter over the last 30 years — and survival rates also up — our rising and aging population means 1.7 million Australians are likely to die from cancer by 2040, according to the Cancer Council’s estimates.  

The strategies countries are contemplating to comprehensively beat cancer, all involve a mix of preventative, early intervention measures and research-led innovation .

Bowel cancer, for example, is Australia’s most costly cancer by health-system expenditure and has the second-highest rate of cancer death. Academic modelling strongly suggests lifting participation in the successful national screening program from the current 40% to 60% would save over 83,000 lives. This would also save around $2.1 billion in public health expenditure. Australia spends less than 2% of its health budget on preventative programs. But with “investment” thinking starting to take hold across social policy design, federal Health Minister Greg Hunt is keen to give much greater priority to preventative approaches.  

Investing in health

Many of the advances against cancer are being driven by the extraordinary worldwide investment in pharmaceutical cancer research. According to the American Cancer Society scientists have learned more about cancer in the last two decades than had been learned in all the centuries preceding, and it is the growth in our knowledge of cancer biology has led to remarkable progress in cancer prevention, early detection, and treatment.

There are now over 800 cancer medicines currently in industry research pipelines, with Australia considered a leader in immuno-oncology drugs. This has created a major opportunity to develop Australia’s pharmaceutical research sector.

The surge in cancer research is challenging health policy makers, regulators and researchers, who are balancing the demand for early access, solid clinical evidence to support therapeutic claims and the high research costs often associated with pharmaceutical development.

Accelerating breakthroughs

Waiting times for drug access in Australia are long by global standards. A variety of papers and reviews have precipitated changes have been implemented to ensuring that Australians are not disadvantaged relative to other patients in comparable nations when it comes to accessing the most up-to-date breakthrough cancer medicines.

A further 1400 drugs were last week listed by the federal government on the Pharmaceutical Benefits Scheme, including chemotherapy medication drug capecitabine. On the weekend the prime minister announced  an improved version of cervical cancer vaccine, Gardasil 9 would be made available free to all 12 and 13 year olds. The government is also expected to announce today the PBS listing of the leukaemia and lymphoma drug imbruvica.

 But it is the particular life ending characteristics of many cancers, and the prevalence of cancer in people’s “healthy years” that has challenged traditional drug evaluation regulatory systems and the evidentiary frameworks they should apply. Valuing the long tail of benefits from cancer medicines is problematic, as is costing the research infrastructure need to support large scale innovation and breakthrough treatments .

About the author
Tom Burton

By Tom Burton

Tom Burton is the former publisher of The Mandarin. He has served in various public administration roles, specialising in the media and communications sector. He was a Walkley Award-winning journalist and executive editor of The Sydney Morning Herald. He worked as Canberra bureau chief for the Australian Financial Review and as managing editor of smh.com.au. He most recently worked at the Australian Communications and Media Authority.

People: David Taylor Greg Hunt Obama

Companies: Kings College University College of London

Departments: Department of Health Pharmaceutical Benefits Scheme

Partners: MSD

Tags: cancer disease prevention Immuno-Oncology innovation oncology pharmaceutical research population health preventative medicine public health

Login
Please login to comment
2 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
George Darroch
George Darroch
4 years ago

We could do a lot more in prevention.

For example, Australia’s extremely successful smoking cessation advertising has been on pause for years now, and we’re not seeing the decline in smoking rates we were. Public concern about tobacco has declined, although it is still the leading cause of cancer fatalities in Australia.

Similarly, none of the recent actions on obesity endorsed by a coalition of medical organisations has been taken up by the government. Obesity and diet are the cause of many preventable cancers, and alcohol consumption is responsible for many more. We’re stagnating in prevention, and the result is a large spend on cancer treatment, and much more unnecessary suffering and death.

0
Ian Parry-Okeden
Ian Parry-Okeden
4 years ago

The approval process for drugs in Australia is laughable. You point out “waiting times for drug access in Australia are long by global standards” but the entire regulatory framework for all drugs is costing billions.
With terminal diagnosis there is no logic in restricting the use of experimental drugs let alone in denying PBS subsidies. Some immunology drugs still under testing but which are clearly keeping cancer sufferers alive are costing patients $10,000 a month and more.
(and on the subject of rising health costs: The health budget could be reduced significantly by reviewing the requirements for patients to regularly attend GP consultations simply to renew prescriptions for medicines they have been taking for years. If a patient with a chronic condition is clearly going to be continuing to take a drug for years ahead, why require so many consultations?

0

The essential resource for effective
public sector professionals

Check out the Latest

By Tom Burton

Monday October 9, 2017
Tom Burton
Text size: A A A

Upcoming Events

01
Apr
Postgraduate studies in regulation and governance at ANU RegNet
14
Jul
Building Visibility + Influence for Women in the Public Sector – MASTERCLASS
29
Jul
Breakfast Briefing: Building and retaining the public sector workforce
03
Aug
Playing Bigger: Uplevelling Influence + Impact for Public Sector Leaders – ONLINE PROGRAM
15
Aug
CILT International Diploma in Logistics and Transport (Public-Sector)
View Calendar

Partner Content

Meeting in the middle: How governments and Indigenous communities can work together, differently
Promoted

Meeting in the middle: How governments and Indigenous communities can work together, differently

Whitepaper: Achieving patient centricity through data-driven care

Whitepaper: Achieving patient centricity through data-driven care

eBook: How to build a Healthy Performance Culture

eBook: How to build a Healthy Performance Culture

Latest Jobs


  • Head of Programs

    Cranlana Centre for Ethical Leadership at Monash University

    • VIC CBD
    Closing date 22nd July, 2022
    5 days ago Full Time - Fixed Term
  • General Manager Decision Support Services

    Bureau of Meteorology

    • National
    Closing date 10th July, 2022
    6 days ago Full Time - Ongoing
  • Multiple Directors - Engagement, Partnerships and Communications

    Department of Customer Service

    • NSW CBD, Regional
    Closing date 1st June, 2022
    1 month ago Full Time - Fixed Term
  • Executive Director Corporate Services - Canberra, Melbourne or Sydney

    Australian Commission for Law Enforcement Integrity

    • VIC CBD
    Closing date 3rd July, 2022
    8 days ago Full Time - Ongoing
  • Executive Director Corporate Services - Canberra, Melbourne or Sydney

    Australian Commission for Law Enforcement Integrity

    • ACT CBD, Regional
    Closing date 3rd July, 2022
    8 days ago Full Time - Ongoing
  • Executive Director Corporate Services - Canberra, Melbourne or Sydney

    Australian Commission for Law Enforcement Integrity

    • NSW
    Closing date 3rd July, 2022
    8 days ago Full Time - Ongoing
Search All Jobs

Login

Get Premium now. Not ready? Get the free Daily newsletter.

Forgot password?

Share via email

Access your 3 free Mandarin Premium articles

As part of your free trial you will receive 'The Juice', The Mandarin's daily free newsletter, the 'Premium wrap' every Saturday and marketing emails. You can opt out at any time.
Content
  • Small Logo
  • News
  • Research Series
  • Features
  • Portfolios
  • Jurisdictions
  • New Zealand
  • People & Capability
  • Thought Leadership
  • Editors' Picks
  • Resource Library
  • Site Map
Products & Services
  • Small Logo
  • The Juice Newsletter
  • Partner & Advertising solutions
  • Mandarin Live
  • Public Sector Events Calendar
  • Partner Content
  • Premium
  • Careers
Legal
  • Small Logo
  • Privacy Policy
  • Terms of Usage
  • Code of Conduct
Connect
  • Small Logo
  • About Us
  • Contact Us
  • Support
  • Our Team
Social
Copyright © The Mandarin
Private Media logo CRIKEY SMARTCOMPANY
wpDiscuz